FDA Accepts Rituxan Biosimilar for Review

The FDA has accepted Sandoz’ application for approval of its rituximab biosimilar to Rituxan.

Rituxan treats cancers of the blood, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia, as well as immunological diseases such as rheumatoid arthritis.

Rituxan is a Biogen brand jointly marketed by Biogen and Genentech USA.